TacticScaleWhat ANI Pharmaceuticals Does & How It Makes Money (ANIP)
Updated October 2026 · reflects ANI Pharmaceuticals's latest reported financials
Specialty drugmaker making branded and generic medicines. ANI earns revenue by selling its branded and generic drugs to national wholesalers, specialty and retail pharmacies, distributors, mail order houses, group purchasing organizations, hospitals, and healthcare providers.
How ANI Pharmaceuticals makes money
ANI earns revenue by selling its branded and generic drugs to national wholesalers, specialty and retail pharmacies, distributors, mail order houses, group purchasing organizations, hospitals, and healthcare providers. It makes a wide range of dosage forms in-house, including oral solids, semi-solids, liquids, topicals, and injectables.
What ANI Pharmaceuticals does
ANI Pharmaceuticals is a U.S.-based biopharmaceutical company, headquartered in Baudette, Minnesota, that develops, manufactures, and markets both branded and generic drugs. Its branded products include Cortrophin gel and the ophthalmic products ILUVIEN and YUTIQ, alongside injectables and softgel capsules. ANI can manufacture many dosage forms, including oral solids, semi-solids, liquids, topicals, controlled substances, and potent products. It sells to national wholesalers, specialty and retail pharmacies, distributors, mail order houses, group purchasing organizations, hospitals, and healthcare providers, both in the U.S. and internationally. The company was incorporated in 2001.
Products & services
- Cortrophin Gel
- ILUVIEN
- YUTIQ
- Injectables
- Softgel capsules
- Generic oral solid dose products
What is ANI Pharmaceuticals worth?
On an owner-earnings DCF, ANI Pharmaceuticals's most-likely value is about $193 versus a recent price near $74 (161% below fair value). But TacticScale only calls a stock undervalued when the price sits below its conservative no-growth floor (~$82) with a margin of safety — so the honest verdict here is “Fairly priced — no edge.” Fair value earns its keep only at the extremes, not in the wide middle.
Price sits in the normal range — fair value isn't actionable here; it earns its keep only when price drops below the no-growth floor, or runs to roughly double the optimistic case.
Analysis, not advice. Fair value is a margin-of-safety estimate from a deterministic owner-earnings DCF, not a price target or recommendation. See the full breakdown →
Related companies
Amneal Pharmaceuticals (AMRX) · North China Pharmaceutical Company.Ltd (600812.SS) · Amgen (AMGN) · Anhui Anke Biotechnology (Group) (300009.SZ)